Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome |
| |
| Authors: | Emilia Montagna Patrick Maisonneuve Nicole Rotmensz Giuseppe Cancello Monica Iorfida Alessandra Balduzzi Viviana Galimberti Paolo Veronesi Alberto Luini Giancarlo Pruneri Luca Bottiglieri Mauro G. Mastropasqua Aron Goldhirsch Giuseppe Viale Marco Colleoni |
| |
| Affiliation: | 1. Department of Medical Oncology and INSERM U981, Institut Gustave Roussy, Villejuif, France;2. Department of Medicine I and Clinical Division of Oncology, Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria;1. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA;2. Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA;3. Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA;4. Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA;5. Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA;6. Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA;7. Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA;1. International Breast Cancer Study Group, Division of Medical Oncology, European Institute of Oncology, Milan, Italy;2. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA;3. International Breast Cancer Study Group and University of Sydney, Sydney, Australia;4. International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA;5. Internal Medicine/Oncology, Institut Jules Bordet, Brussels, Belgium;6. Breast Center, Kantonsspital St Gallen, St Gallen;7. Tumor and Breast Center ZeTuP, St Gallen, Switzerland;1. Department of Pathology, Centre Jean-Perrin, Clermont-Ferrand, France;2. EA 4677 Université d''Auvergne, Clermont-Ferrand, France;3. Division of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy |
| |
| Abstract: | BackgroundThis study assesses outcome in terms of disease-free survival (DFS) and overall survival (OS) of special types of triple-negative breast cancer (TNBC).Patients and MethodsWe identified 8801 women with first primary nonmetastatic breast cancer operated on at the European Institute of Oncology between 1997 and 2005. Of these patients, 781 consecutive patients with immunohistochemically defined TNBC were selected for the analyses. We explored patterns of recurrence by histologic type. Median follow-up was 5.7 years (range 0-13 years).ResultsThe 5-year DFS was 77% for TNBC, 68% for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and 84% and 95% for luminal B and luminal A breast cancer, respectively. From 781 TNBC subtypes, 693 cases (89%) were classified as ductal not otherwise specified (NOS) (invasive ductal carcinoma [IDC]), 29 were classified as apocrine (3.7%), 18 (2.3%) were classified as lobular, 10 (1.2%) were classified as adenoid cystic, and 10 (1.2%) were classified as metaplastic. Five-year DFS and OS were 77% and 84% for patients with ductal carcinoma, 56% and 89% for patients with metaplastic carcinoma, and both 5-year DFS and OS were 100% for patients with adenoid cystic and medullary carcinomas, respectively.ConclusionDistinct prognostic implications may derive from the specific histotype of TNBC. The identification of these special types has a significant clinical utility and should be considered in therapeutic algorithms. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
